Access challenges associated with high‐cost pharmaceuticals have jumpstarted discussion of solutions ranging from state‐based boards reviewing drug price increases to harnessing Medicare's purchasing power for “price negotiation” to old‐fashioned price‐setting. Consumers, increasingly frustrated with high costs for complex generics such as the EpiPen and novel, million‐dollar therapies like Zolgensma, are demanding government action. High‐cost pharmaceuticals may be classified into three groups: new modalities, such as gene therapy; old generic, small molecule drugs; and biologics. We focus here on biologics and explore potential solutions.
展开▼
